Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15678339 | 0.88 | SLC6A4 (0.56) | SLC6A4KDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL1122134 | 0.85 | SLC6A4 (0.85) | SLC6A4CYP2D6 | |
| SCHEMBL13226846 | 0.83 | SLC6A4 (0.63) | SLC6A4MEN1KMT2ASLC6A3DRD2 | |
| SCHEMBL29005985 | 0.82 | SLC6A4 (0.62) | SLC6A4DRD2DRD4DRD3 | |
| SCHEMBL12881233 | 0.80 | SLC6A4 (0.68) | SLC6A4MEN1KMT2ASLC6A3DRD2 | |
| SCHEMBL1399199 | 0.80 | SLC6A4 (0.62) | SLC6A4KDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL24688682 | 0.80 | SLC6A4 (0.59) | SLC6A4DRD2DRD4DRD3 | |
| SCHEMBL29985571 | 0.80 | SLC6A4 (0.59) | SLC6A4DRD2DRD4DRD3 | |
| SCHEMBL24328228 | 0.80 | SLC6A4 (0.59) | SLC6A4DRD2DRD4DRD3 | |
| SCHEMBL24243716 | 0.79 | SLC6A4 (0.70) | SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8945397-B2 | Methods of inhibiting cyanobacteria growth by administering gramine derivatives | CYANOTROL, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-8945397-B2 | Methods of inhibiting cyanobacteria growth by administering gramine derivatives | CYANOTROL, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140110350-A1 | METHODS OF INHIBITING CYANOBACTERIA GROWTH BY ADMINISTERING GRAMINE DERIVATIVES | SAN FRANCISCO STATE UNIVERSITY (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140110350-A1 | METHODS OF INHIBITING CYANOBACTERIA GROWTH BY ADMINISTERING GRAMINE DERIVATIVES | SAN FRANCISCO STATE UNIVERSITY (US) | 2014-04-24 | — | — | US | disclosed |
| US-20090281114-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009137733-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2007075931-A2 | REACTIVE HETEROCYCLIC DERIVATIVES AND METHODS FOR THEIR SYNTHESIS AND USE | BIOSITE INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1222167-A2 | METHOD FOR PRODUCING INDOLE DERIVATIVES ON A SOLID PHASE | MERCK PATENT GmbH (DE) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001023353-A2 | METHOD FOR PRODUCING INDOLE DERIVATIVES ON A SOLID PHASE | MERCK PATENT GMBH (DE) | 2001-04-05 | — | — | WO | disclosed |
| US-5434154-A | Serotonin agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| US-5300506-A | Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281114-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | HTR5A, TPH2, IDO2 | SLC6A4 104/4885KDM4E 1638/4885MEN1 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.